DelveInsight’s ‘Toll-Like Receptor Agonist Pipeline Insight 2022’ report provides comprehensive global coverage of available, marketed, and pipeline toll-like receptor agonist therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the toll-like receptor agonist pipeline domain.
For toll-like receptor agonist emerging drugs, the toll-like receptor agonist pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Toll-Like Receptor Agonist Pipeline Report
- Over 60+ toll-like receptor agonist pipeline therapies are in various stages of development, and their anticipated acceptance in the toll-like receptor agonist market would significantly increase market revenue.
- Leading toll-like receptor agonist companies developing novel drug candidates to improve the toll-like receptor agonist treatment landscape include InDex Pharmaceuticals, Mologen, Exicure, Birdie Biopharmaceuticals, Seven and Eight Biopharmaceuticals, Primmune Therapeutics, Pattern Pharma, Silverback Therapeutics, Hoffman-La-Roche, Ascendis Pharma, Nektar therapeutics, BioNTech, Highlight Therapeutics, PrEP Biopharm, TriSalus Life Sciences, Gilead Sciences, Tallac Therapeutics, Inc., ALX Oncology Holdings Inc., Checkmate Pharmaceuticals, AIM ImmunoTech, Scopus BioPharma, BrightPath Biotherapeutics, NapaJen Pharma, Ena Respiratory, Revelation Biosciences, Immune Design, Protara Therapeutics, Galderma, Bolt Biotherapeutics, Jiangsu Hengrui Medicine Co., Novartis, Elicio Therapeutics, Statera BioPharma, and others.
- Promising toll-like receptor agonist pipeline therapies in various stages of development include P2PAR-100, SBT8230, RG 6115, TransCon TLR 7/8 agonist, NKTR-262, BNT411, BO112, PrEP-001, BDB001, Cobitolimod, Tilsotolimod, SD 101, Lefitolimod, Vesatolimod, Vidutolimod, Rintatolimod, DUET 01, NJB 834, INNA 051, Glycopyranosyl lipid adjuvant, G 100, TARA-002, RO 7020531, Resiquimod, BDC 1001, SHR 2150, LHC 165, PRX 034, ELI 002, IDX 9059, Entolimod, and others.
- In February 2022, Primmune Therapeutics presented interim data related to PRTX007, a novel, orally administered, small molecule toll-like receptor 7 (TLR7) specific agonist that is currently in Phase 1 development, at the Conference on Retroviruses and Opportunistic Infections (CROI). Oral administration of PRTX007 in this first-in-human study of healthy volunteers exhibited a favorable safety profile, rapid absorption and conversion to TLR7 agonist PRX034, and activation of the innate immune system without causing inflammation.
- Pattern’s lead product, P2PAR-100, is an immunotherapeutic that activates innate immune cells to kill cancer cells and safely activates an efficacious innate and adaptive immune response.
Request a sample and discover the recent breakthroughs happening toll-like receptor agonist pipeline landscape @Toll-Like Receptor Agonist Pipeline Report
Toll-Like Receptor Agonist Overview
Toll-like receptors (TLRs) are immune sentinels that detect pathogen-associated molecular patterns (PAMPs) such as unmethylated double-stranded DNA (CpG), single-stranded RNA (ssRNA), lipoproteins, lipopolysaccharide (LPS), and flagellin. Once these microbes have passed through physical barriers such as the skin or the mucosa of the digestive tract, they are recognized by TLRs, which activate immune cell responses. In the developing embryo of Drosophila, the Toll receptor was discovered to be an essential receptor for dorso-ventral patterning. The TLR family has ten members in humans (TLR1-TLR10) and twelve in mice (TLR1-TLR9, TLR11-TLR13). TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10 are found on the cell membrane in humans, while TLR3, TLR7, TLR8, and TLR9 are found in intracellular vesicles.
Toll-Like Receptor Agonist Pipeline Analysis: Drug Profile
Cobitolimod: InDex Pharmaceuticals
Cobitolimod is a first-in-class Toll-like receptor 9 (TLR9) agonist that can provide an anti-inflammatory effect locally in the large intestine, potentially causing mucosal healing and symptom relief in ulcerative colitis. In the Phase IIb study CONDUCT, cobitolimod met the primary endpoint and demonstrated an exceptional combination of efficacy and safety.
Tilsotolimod: Idera Pharmaceuticals
Tilsotolimod is a synthetic Toll-like receptor 9 agonist under investigation. Tilsotolimod intramuscular injection has been shown to promote both innate (Type-I IFN, antigen presentation) and adaptive (T cells) immune activation. Tilsotolimod has received both Fast Track and Orphan Drug designation from the FDA, and it is being tested in various tumor types and combinations with various checkpoint inhibitors.
Toll-Like Receptor Agonist Pipeline Therapies and Key Companies
- Tilsotolimod: Idera Pharmaceuticals
- Cobitolimod: InDex Pharmaceuticals
- E5564: Eisai Co Ltd
- BDB001: Seven and Eight Biopharmaceuticals
- PrEP-001: PrEP Biopharm
- BO112: Highlight Therapeutics
- BNT411: BioNTech
- NKTR-262: Nektar therapeutics
- TransCon TLR 7/8 agonist: Ascendis Pharma
Learn more about the toll-like receptor agonist emerging pipeline therapies @Toll-Like Receptor Agonist Clinical Trials
Toll-Like Receptor Agonist Pipeline Therapeutics Assessment
- By Product Type
-
- Monotherapy
- Combination Therapy
- By Stage
-
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- By Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Scope of the Toll-Like Receptor Agonist Pipeline Report
- Coverage: Global
- Key Toll-Like Receptor Agonist Companies: InDex Pharmaceuticals, Mologen, Exicure, Birdie Biopharmaceuticals, Seven and Eight Biopharmaceuticals, Primmune Therapeutics, Pattern Pharma, Silverback Therapeutics, Hoffman-La-Roche, Ascendis Pharma, Nektar therapeutics, BioNTech, Highlight Therapeutics, PrEP Biopharm, TriSalus Life Sciences, Gilead Sciences, Tallac Therapeutics, Inc., ALX Oncology Holdings Inc., Checkmate Pharmaceuticals, AIM ImmunoTech, Scopus BioPharma, BrightPath Biotherapeutics, NapaJen Pharma, Ena Respiratory, Revelation Biosciences, Immune Design, Protara Therapeutics, Galderma, Bolt Biotherapeutics, Jiangsu Hengrui Medicine Co., Novartis, Elicio Therapeutics, Statera BioPharma, and others.
- Key Toll-Like Receptor Agonist Pipeline Therapies: P2PAR-100, SBT8230, RG 6115, TransCon TLR 7/8 agonist, NKTR-262, BNT411, BO112, PrEP-001, BDB001, Cobitolimod, Tilsotolimod, SD 101, Lefitolimod, Vesatolimod, Vidutolimod, Rintatolimod, DUET 01, NJB 834, INNA 051, Glycopyranosyl lipid adjuvant, G 100, TARA-002, RO 7020531, Resiquimod, BDC 1001, SHR 2150, LHC 165, PRX 034, ELI 002, IDX 9059, and others.
Dive deep into rich insights for toll-like receptor agonist emerging therapies and assessment, visit @ Toll-Like Receptor Agonist Emerging Therapies
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Overview |
| 4. | Pipeline Therapeutics |
| 5. | Late Stage Products (Phase III) |
| 6. | Mid Stage Products (Phase II) |
| 7. | Early Stage Products (Phase I/II) |
| 8. | Preclinical Stage Products |
| 9. | Discovery Stage Products |
| 10. | Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Collaborations Assessment- Licensing / Partnering / Funding |
| 13. | Unmet Needs |
| 14. | Market Drivers and Barriers |
| 15. | Appendix |
| 16. | About DelveInsight |
For further information on the toll-like receptor agonist current pipeline therapeutics, reach out@ Toll-Like Receptor Agonist Therapeutics Assessment
Related Reports
Toll-Like Receptor 3 (TLR-3) Agonist Pipeline
DelveInsight’s “Toll-Like Receptor 3 (TLR-3) Agonist Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Toll-Like Receptor 3 (TLR-3) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products and key Toll-Like Receptor 3 companies such as AIM ImmunoTech, PrEP Biopharm, Oncovir, Bioncotech Therapeutics, and others.
Toll-Like Receptor 7, 8 (TLR-8) Agonist Pipeline
DelveInsight’s “Toll-Like Receptor 7, 8 (TLR-8) Agonist Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Toll-Like Receptor 7, 8 (TLR-8) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products and key Toll-Like Receptor 7, 8 (TLR-8) Agonist companies such as UroGen Pharma, Silverback Therapeutics, Seven and Eight Biopharmaceuticals, Nektar Therapeutics, Ascendis Pharma, CureVac, Cello Therapeutics, Zhimeng Biopharma, and others.
Toll-Like Receptor 4 (TLR-4) Agonist Pipeline
DelveInsight’s “Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Toll-Like Receptor 4 (TLR-4) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products and key Toll-Like Receptor 4 (TLR-4) Agonist companies such as Eisai, Akaza Bioscience, OPNT-003, GeNeuro, MN-166 (ibudilast), Orexo, and others.
Toll-Like Receptor Modulators Pipeline
DelveInsight’s “Toll-Like Receptor Modulators Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in the Toll-Like Receptor Modulators pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products and key Toll-Like Receptor Modulators companies such as InDex Pharmaceuticals, Idera Pharmaceuticals, Eisai, Pulmotect, Oncovir, and others.
Toll-Like Receptor 9 (TLR-9) Modulator Pipeline
DelveInsight’s “Toll-Like Receptor 9 (TLR-9) Modulator Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Toll-Like Receptor 9 (TLR-9) Modulator pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products and key Toll-Like Receptor 9 (TLR-9) Modulator companies such as InDex Pharmaceuticals, Scopus BioPharma, BrightPath Biotherapeutics, Checkmate Pharmaceuticals, Mologen, Exicure, and others.
CD137 Agonist Antibody Pipeline
DelveInsight’s “CD137 Agonist Antibody Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the CD137 Agonist Antibody pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products, and key CD137 Agonist Antibody companies involved, such as Agenus, Lyvgen, Compass Therapeutics, Bristol Myers Squibb, F-star Therapeutics, Adagene, Bicycle Therapeutics, Alligator Biosciences, Pfizer, and others.
CD33 Antigen Inhibitors Pipeline
DelveInsight’s “CD33 Antigen Inhibitors Pipeline Insight, 2022,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the CD33 Antigen Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products, and key CD33 Antigen Inhibitors companies involved, such as PersonGen Biomedicine, Y-mAbs Therapeutics, Alector, GT Biopharma, iCell Gene Therapeutics, and many others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Hemophilia A Market | Hemostasis Market | Peptic Ulcers Market
Related Healthcare Blogs
- Toll-Like Receptor Modulators: Emerging therapy for many indications
- A promising immune-stimulating target
- Cost ineffective Orphan Drugs limit the access
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187